Swedish Orphan Biovitrum AB (publ) (Sobi) has elected to add the preclinical
rFVIIIFc-XTEN-vWF fusion molecule to the company's collaboration with Biogen
Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec
and Amunix signed a worldwide license agreement in April 2014. Under the terms
of Sobi and Biogen Idec's agreement, Sobi has the right to elect to include the
rFVIIIFc-XTEN-vWF fusion molecule in the collaboration. Sobi is required to make
a payment to Biogen Idec to include this program in the collaboration agreement.

"We are pleased to include this new and innovative technology in our
collaboration with Biogen Idec", said Geoffrey McDonough, CEO and President
Sobi. "Although at an early stage, the XTEN technology has the potential to
further extend FVIII half-life and could one day potentially become a next-
generation long-acting factor for people with haemophilia A."

Biogen Idec and Sobi are collaborators in the development and commercialisation
of Eloctate(TM) and Alprolix(TM) for haemophilia A and B. Biogen Idec leads
development, has manufacturing rights, and has commercialisation rights in North
America and all other regions in the world excluding the Sobi territory. Sobi
has the right to opt in to assume final development and commercialisation in
Europe, including Russia, the Middle East and Northern Africa. XTEN will now be
added to this collaboration with similar terms to those of Eloctate and
Alprolix.

- - -

About Haemophilia A

Haemophilia A is a rare, chronic, genetic disorder in which the ability of a
person's blood to clot is impaired, due to missing or reduced levels of a
protein known as factor VIII. People with haemophilia A experience recurrent and
extended bleeding episodes that cause pain and irreversible joint damage. Some
of these bleeding episodes can be life-threatening. According to the World
Federation of Hemophilia, an estimated 142,000 people worldwide are identified
as living with haemophilia A.[1] Prophylactic injections of factor VIII can
temporarily replace the clotting factor necessary to control bleeding and
prevent new bleeding episodes.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
(€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.



For more information please contact

Media relations                                         Investor relations
Charlotte af Klercker                                Jörgen Winroth
Senior Communications Manager            Vice President, Head of Investor
Relations
T: +46 707 297 327                                  T:
+1 347-224-0819, +1 212-579-0506
charlotte.afklercker@sobi.com                 jorgen.winroth@sobi.com



The above information was released for public distribution on 19 September
2014, at 08:00 CET.


--------------------------------------------------------------------------------

[1] World Federation of Hemophilia. Annual Global Survey 2012.
http://www1.wfh.org/publications/files/pdf-1574.pdf


[HUG#1856982]